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iDITORIAL COMMENT
schemia, Revascularization,
nd Perioperative Troponin
levation After Vascular Surgery*
ebabrata Mukherjee, MD, FACC,
im A. Eagle, MD, FACC
nn Arbor, Michigan
erioperative cardiac risk may be related in several ways to
he type of noncardiac surgery being performed. Some types
f noncardiac surgery identify a group of patients at in-
reased risk for concomitant cardiac disease based on shared
isk factors that predispose patients to both noncardiac and
ardiac disease. The most notable example of this relation-
hip is seen with vascular surgery and coronary artery disease
CAD). The same factors that result in atherosclerosis of
he peripheral arteries or the aorta may also predispose one
o the development of CAD. Among such patients, CAD
ay be known or occult, with no symptoms because of the
hysical limitations associated with significant peripheral
ascular disease. Risk stratification and optimal periopera-
ive management are particularly important in these high-
isk patients. As seen with patients undergoing coronary
evascularization, several studies have demonstrated that
ven minor elevations in perioperative serum troponin
oncentrations are associated with significantly worse long-
erm survival after vascular surgery (1–3).
See page 569
The pathophysiology of perioperative myocardial infarc-
ion (MI) may differ from that of an MI occurring in the
on-operative setting. Usually the rupture of a coronary
laque leads to platelet aggregation, which leads to throm-
us formation and dynamic obstruction. In contrast, plaque
upture occurs in approximately half of perioperative MIs
4,5); the remaining 50% may be the result of a prolonged
mbalance between myocardial oxygen supply and demand
n the setting of fixed CAD (6). Oxygen demand may be
ncreased by tachycardia and hypertension resulting from
ostoperative pain, withdrawal of anesthesia, or shifts in
ntravascular volume. An autopsy study by Dawood et al. (4)
uggested that the underlying pathophysiology of most fatal
erioperative MI is the disruption of an atherosclerotic
*Editorials published in the Journal of the American College of Cardiology reflect the
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merican College of Cardiology.
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ianofi.laque, leading to coronary thrombosis and dynamic ob-
truction of coronary vessels.
Several strategies, including coronary revascularization,
ave been used in patients with vascular surgery to reduce
he incidence of perioperative MI and other complications.
lthough there are no prospective trials testing the impact
f either preoperative coronary artery bypass grafting or
ercutaneous coronary intervention on perioperative cardiac
orbidity and mortality rates, several retrospective studies
ave suggested that patients with successful previous coro-
ary revascularization have a low risk of perioperative
ardiac events during noncardiac surgery and that the risk of
eath may be comparable with that among patients with no
linical evidence of CAD (7–9). In this issue of the Journal,
andesberg et al. (10) prospectively collected data in 501
onsecutive vascular procedures. Ischemia on thallium scan
as associated with a 49% incidence of low-level and 22.4%
ncidence of conventional troponin elevation. On multivar-
ate analysis, ischemia on thallium was the most important
redictor of both low-level and conventional troponin
levations (adjusted odds ratio 2.5 and 2.7, respectively; p
0.02 and 0.04, respectively), whereas previous coronary
evascularization predicted fewer troponin elevations (ad-
usted odds ratio  0.35 and 0.16, respectively; p  0.045
nd 0.022, respectively). The authors concluded that tropo-
in elevations occur frequently after vascular surgery. This
henomenon is strongly associated with postoperative isch-
mia, which is predicted by inducible ischemia on thallium
can and possibly reduced by preoperative revascularization.
This study is important in several respects. First, the
nalysis establishes an association between a high incidence
f minor troponin elevation and preoperative CAD. Sec-
nd, the study demonstrates the potential beneficial effect of
oronary revascularization in reducing perioperative tropo-
in elevation, which in turn has been shown to affect
onger-term clinical outcome. Third, the data confirm
ecent reports of the underuse of evidence-based medical
herapies such as beta-blockers, statins, and angiotensin-
onverting enzyme inhibitors in patients undergoing vascu-
ar procedures (11,12).
The study raises an important question as to whether
atients undergoing vascular surgery should be routinely tested
ith preoperative imaging perfusion test and undergo revascu-
arization if there is evidence of ischemia. Cardiac complica-
ions account for 50% to 60% of the morbidity and mortality
bserved after vascular surgical procedures, and appropriate
reoperative measures may significantly reduce risk. In a
elective review of several thousand vascular surgical procedures
carotid endarterectomy, aortic aneurysm resection, and lower-
xtremity revascularization), Hertzer (13) found that cardiac
omplications were responsible for approximately half of all
erioperative deaths and that fatal events were nearly five times
ore likely to occur in the presence of standard preoperative
ndicators of CAD. Although the sensitivity of thallium
maging for detecting patients at increased risk is excellent, one
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August 4, 2004:576–8 Editorial Commentf its limitations for preoperative screening is its low specificity
nd positive predictive value. To improve the value of risk
tratification, many reports have suggested using a combina-
ion of clinical markers and noninvasive test results. Eagle et al.
14) first reported on using the assessment of clinical markers
history of angina, MI, congestive heart failure, diabetes, and
-wave on electrocardiogram) and thallium redistribution to
dentify a low-risk subset of patients in patients undergoing
ascular surgery. The authors demonstrated that patients with-
ut any of these clinical markers did not require dipyridamole
hallium testing. However, thallium redistribution had a sig-
ificant predictive value in patients with one or two clinical risk
actors. Within this group, 2 of 62 (odds ratio 3.2%; 95%
onfidence interval 0% to 8%) patients without thallium
edistribution had events, compared with 16 events in 54
atients (odds ratio 29.6%; 95% confidence interval, 16% to
4%) with thallium redistribution (14). L’Italien et al. (15)
eported the results of a Bayesian model for perioperative risk
ssessment in vascular surgery candidates that combined clin-
cal variables with dipyridamole thallium findings. This anal-
sis examined the type of procedure, specific institutional
omplication rates, and other clinical factors in a sequential
anner followed by the addition of the dipyridamole thallium
ndings. The addition of dipyridamole thallium data reclassi-
ed 80% of the moderate-risk patients into low- (3%) and
igh- (19%) risk categories (p  0.0001) but provided no
tratification for patients classified as low or high risk according
o the clinical model. Despite these findings and the suggestion
o use noninvasive testing only in patients of intermediate
linical risk, the identification of truly low-risk patients may be
ifficult based on clinical variables alone in patients with
ascular disease. It also has been shown that even in patients
ho are at low risk clinically, a finding of ischemia with
ipyridamole thallium testing is associated with an increase in
he risk of MI by as much as 10-fold. In the study by
andesberg et al. (10) and Fleisher et al. (16), patients did not
ndergo thallium scanning if they had coronary angiography
ithin the year prior to surgery with no subsequent change in
ymptoms, a negative exercise stress test with no history of
AD, and no clinical evidence of CAD. Patients who under-
ent bypass surgery in the previous five years or percutaneous
oronary intervention from six months to five years previously
nd were free of clinical evidence of ischemia also may be
ncluded in this group and generally have surgery without
urther testing, particularly if they are functionally very active
16).
Finally, one needs to consider the suboptimal use of beta-
lockers (40%) and statins (30%) in this cohort, both of
hich have been demonstrated to reduce periprocedural events
n patients undergoing vascular surgery (17,18). Whether
oronary revascularization reduces periprocedural troponin el-
vation and clinical events in the presence of optimal medical
herapy is not yet known. Until then, the indications for
oronary revascularization should include patients with poorly
ontrolled ischemic symptoms despite excellent medical ther-
py or patients with a large ischemic burden (25% of the leftentricle) on stress perfusion imaging (19). In patients with
uch extensive ischemia, effective beta-blockade may not be
ufficient to reduce the rate of perioperative cardiac complica-
ions (20). Whether coronary revascularization is offered or
ot, aggressive medical and preventive therapies are essential to
mprove long-term outcomes.
eprint requests and correspondence: Dr. Kim A Eagle, Divi-
ion of Cardiology, University of Michigan Cardiovascular Center,
00 North Ingalls, NIB 8B02, Ann Arbor, Michigan 48109-0477.
-mail: keagle@umich.edu.
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